Open access

NEWS - Oncology

ASCO 2018: Shortening Adjuvant Trastuzumab to 6 Months in Patients With HER2-Positive Early Breast Cancer Is Effective and Reduces Cardiac Toxicities – The ASCO Post (free)

Commentaries: Test of Herceptin Finds Briefer Treatment Can Work, With Fewer Side Effects – NPR (free) AND Shorter drug treatment OK for many breast cancer patients – Associated Press (free) AND For Women With Early Breast Cancer, Herceptin Treatment Can Be Much Shorter – The New York Times (10 articles per month are free)

““For women with early-stage breast cancer who needed the drug Herceptin, 6 months of treatment were as good as 12, a major study found. Less risk of side effects, less cost, less time “being a patient.”” (via @NYTHealth see Tweet)


Perspective: Demand cancer drugs that truly help patients – Nature (free)

“Drug regulators and trial designs should assess benefits that actually matter to people with cancer, says Ajay Aggarwal”


Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma – NEJM (link to abstract – $ for full-text)

Quick Take Video Summary: Sunitinib or Nivolumab plus Ipilimumab for Renal-Cell Carcinoma (free)

“Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab”.


Clinical Updates: Palliative radiotherapy – The BMJ (free)

Clinical Update for non-specialists on the benefits, practicalities, and side effects of palliative radiotherapy


FDA In Brief: FDA updates public information about known risk of lymphoma from breast implants (free) AND Breast Implant-Associated Anaplastic Large Cell Lymphoma – FDA Update (free)

Commentaries: More Cases Are Reported of Unusual Cancer Linked to Breast Implants – The New York Times (10 articles per month are free) AND Implant-Related Lymphoma Cases Rise – More than 400 cases reported to FDA – MedPage Today (free)

“Some 400 to 500 women worldwide have an unusual type of lymphoma linked to breast implants with textured surfaces. Experts say women considering implants should be told”. (via @NYTHealth see Tweet)


#ACC18 – Carvedilol for Prevention of Chemotherapy Related Cardiotoxicity – Journal of the American College of Cardiology (link to abstract – $ for full-text)

Commentaries: Beta Blocker Shows Mixed Results in Protecting Against Chemo-Induced Heart Damage – American College of Cardiology (free) AND Carvedilol Effect in Preventing Chemotherapy Induced CardiotoxicitY – CECCY – American College of Cardiology (free)

Related study from #ACC18: Heart Drugs Prevented Cardiotoxicity in Breast Cancer Treated With Anthracycline and Trastuzumab – American College of Cardiology (free)

“According to the CECCY trial, carvedilol had no effect on left ventricular function in breast cancer patients treated w/ doxorubicin, but did result in a reduction in troponin I levels & diastolic dysfunction”. (via @ACCinTouch see Tweet)


Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)

Commentary: One-off PSA screening for prostate cancer does not save lives – eCancer News (free)

“Largest ever prostate cancer trial – CAP – published in the JAMA. No effect from low intensity PSA screening on prostate cancer mortality at 10 years”. (via @KariTikkinen see Tweet)


Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer – New England Journal of Medicine (free)

“Apalutamide improves castration resistant prostate CA survival compared with… placebo. Why wasn’t it compared w bicalutamide?” (via @RichardLehman1 see Tweet). See Richard Lehman’s point of view


Page 1 of 41234

Stay updated in your specialty!

No spam, just news
Unsubscribe with one click